Document Type
Poster
Publication Date
2024
Abstract
This literature review will explore if patients in California with left ventricular outflow tract obstruction (LVOTO) taking a single prescription medication that exceeds $250 per 30 day supply will benefit from the passing of California Law AB 948 titled Prescription Drugs in 2023.
A comprehensive literature review on papers comparing prescription medication effectiveness for LVOTO, medication dosing, and price for hypertrophic obstructive cardiomyopathy was completed. Research papers were written by doctors who have treated hypertrophic cardiomyopathy and researchers investigating new drug treatment success. Goodrx.com was used to price suggested pharmacological agents.
Seven drugs were priced at low and high doses. One of the seven drugs typically used to treat LVOTO, disopyramide, was found to exceed California’s law that prevents out of pocket costs above $250 per 30 day supply.
Patients taking LVOTO medication in California do not exceed the $250 prescription drug out of pocket cap when obtaining medication.
Recommended Citation
Arzaga, Yvette, "The Impact of California Law AB 948 on Patient Outcomes in Left Ventricular Outflow Tract Obstruction" (2024). Diagnostic Ultrasound Projects. 8.
https://scholarworks.seattleu.edu/dius-projects/8